Pulmatrix (PULM) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

PULM · Stock Price

USD 1.30-4.90 (-79.03%)

Market Cap: $4.7M

Historical price data

Market Cap: $4.7MPipeline: 13 drugsFounded: 2003Employees: 11-50HQ: Lexington, United States

Sector Ranking#128 in Drug Delivery & Formulation

Overview

Pulmatrix is a clinical-stage biotech focused on developing inhaled therapeutics for serious pulmonary and systemic diseases using its proprietary iSPERSE™ dry powder delivery platform. Its strategy centers on reformulating known drug molecules for inhalation to create new products with potential advantages in speed of onset, efficacy, and patient convenience. Key achievements include advancing its lead candidate, PUR3100 for acute migraine, into Phase 2 clinical development and building a diverse pipeline of 13 candidates. The company aims to leverage its versatile platform through internal development and potential partnerships.

RespiratoryNeurological

Technology Platform

iSPERSE™ is a proprietary engineered dry powder delivery platform designed for high drug loading, stability, and efficient deep lung delivery, enabling both local and systemic administration of therapeutics.

Pipeline

13

13 drugs in pipeline

Drug	Indication	Stage
Itraconazole Powder + Placebo	ABPA	Phase 2
RUT058-60 + Sterile saline for irrigation	Postoperative Wound Infection-deep	Phase 1/2
PUR003 + Placebo	Healthy	Phase 1
PUR0200 + Reference Product	Healthy	Phase 1
PUR118	Chronic Obstructive Pulmonary Disease (COPD)	Phase 1

Opportunities

Pulmatrix's iSPERSE™ platform offers a versatile approach to reformulating drugs for inhalation, creating opportunities in large markets like migraine and COPD where current treatments have limitations.

Positive Phase 2 data for PUR3100 could validate the platform for systemic delivery and attract partnership interest.

The company's pipeline of 13 candidates provides multiple value inflection points beyond its lead programs.

Risk Factors

The company faces high clinical development risk, with near-term value heavily dependent on the binary outcome of the PUR3100 Phase 2 trial.

As a pre-revenue micro-cap biotech, Pulmatrix carries significant financial risk and will require additional capital, risking shareholder dilution.

Regulatory hurdles for inhaled products and intense market competition pose further challenges to eventual commercialization.

Competitive Landscape

PUR3100 competes in the crowded migraine market but differentiates by offering potential rapid onset via inhalation, avoiding GI issues. In COPD, PUR1800 aims to challenge systemic steroids by offering localized efficacy with fewer side effects. The iSPERSE™ platform competes with other dry powder technologies, requiring clear clinical proof-of-concept to secure partnerships and market position.